Case Study: Global Top-20 Biopharmaceutical Company enrolls rare disease trial 29 days early with OneStudyTeam's StudyTeam

Top-20 Biopharma Enrolls Rare Disease Trial 4 Weeks Early with StudyTeam

Global Top-20 Biopharmaceutical Company, a global top-20 biopharma with more than 20 therapies on the market and more than 30 in development, was preparing to run a difficult-to-enroll rare disease clinical trial. The sponsor faced inaccurate feasibility estimates, consent challenges, and competition for a limited patient pool, while traditional recruitment tactics such as central advertising, adding more sites, or amending the protocol seemed costly and uncertain. OneStudyTeam’s StudyTeam enrollment performance management solution was brought in early to help address these challenges.

OneStudyTeam deployed StudyTeam across the trial during site activation, giving the sponsor real-time visibility into candidate patients, pre-screening efficiency, I/E criteria analytics, and source tracking. This enabled the sponsor to act quickly, amend the protocol within about two months of the first patient enrolling, and complete enrollment 29 days ahead of schedule. The early finish reduced unnecessary services spend and accelerated time to market, improving revenue potential.